KR20170069413A - Composition comprising extract of germinated black rice as an effective component for prevention or treatment of obesity or of metabolic bone disease - Google Patents
Composition comprising extract of germinated black rice as an effective component for prevention or treatment of obesity or of metabolic bone disease Download PDFInfo
- Publication number
- KR20170069413A KR20170069413A KR1020150176560A KR20150176560A KR20170069413A KR 20170069413 A KR20170069413 A KR 20170069413A KR 1020150176560 A KR1020150176560 A KR 1020150176560A KR 20150176560 A KR20150176560 A KR 20150176560A KR 20170069413 A KR20170069413 A KR 20170069413A
- Authority
- KR
- South Korea
- Prior art keywords
- germinated
- black rice
- extract
- light source
- composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 137
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 208000008589 Obesity Diseases 0.000 title claims abstract description 25
- 235000020824 obesity Nutrition 0.000 title claims abstract description 25
- 241000371652 Curvularia clavata Species 0.000 title claims description 114
- 230000002265 prevention Effects 0.000 title description 4
- 208000029725 Metabolic bone disease Diseases 0.000 title description 2
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 title 1
- 235000021329 brown rice Nutrition 0.000 claims abstract description 42
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 28
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 20
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 14
- 208000018083 Bone metabolism disease Diseases 0.000 claims abstract description 13
- 235000013376 functional food Nutrition 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 99
- 238000000605 extraction Methods 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 239000012046 mixed solvent Substances 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 230000004097 bone metabolism Effects 0.000 claims description 2
- 230000011164 ossification Effects 0.000 claims description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims 1
- 239000000498 cooling water Substances 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 238000002137 ultrasound extraction Methods 0.000 claims 1
- 230000035784 germination Effects 0.000 abstract description 70
- 230000004069 differentiation Effects 0.000 abstract description 42
- 210000001789 adipocyte Anatomy 0.000 abstract description 41
- 206010017076 Fracture Diseases 0.000 abstract description 13
- 230000037118 bone strength Effects 0.000 abstract description 12
- 208000010392 Bone Fractures Diseases 0.000 abstract description 10
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 abstract description 9
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 abstract description 9
- 108010043267 Sp7 Transcription Factor Proteins 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 102000049320 CD36 Human genes 0.000 abstract description 6
- 108010045374 CD36 Antigens Proteins 0.000 abstract description 6
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 abstract description 6
- 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 abstract description 6
- 108010016731 PPAR gamma Proteins 0.000 abstract description 6
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- 238000011633 osteoporosis animal model Methods 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 101710189683 Alkaline protease 1 Proteins 0.000 abstract 1
- 101710154562 Alkaline proteinase Proteins 0.000 abstract 1
- 102100021253 Antileukoproteinase Human genes 0.000 abstract 1
- 101710170876 Antileukoproteinase Proteins 0.000 abstract 1
- 101710112538 C-C motif chemokine 27 Proteins 0.000 abstract 1
- 102100032317 Transcription factor Sp7 Human genes 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 53
- 230000000694 effects Effects 0.000 description 27
- 238000004519 manufacturing process Methods 0.000 description 25
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 23
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 22
- 230000001965 increasing effect Effects 0.000 description 19
- 238000009806 oophorectomy Methods 0.000 description 16
- 230000004072 osteoblast differentiation Effects 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 9
- 102000002624 Sp7 Transcription Factor Human genes 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 8
- 239000000469 ethanolic extract Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 210000000963 osteoblast Anatomy 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- 239000011707 mineral Substances 0.000 description 7
- 235000010755 mineral Nutrition 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- -1 fluoroalkane Chemical compound 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000020084 Bone disease Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 206010031240 Osteodystrophy Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000010866 blackwater Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical compound CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 201000008972 osteitis fibrosa Diseases 0.000 description 2
- 208000005368 osteomalacia Diseases 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- SQCZQTSHSZLZIQ-UHFFFAOYSA-N 1-chloropentane Chemical compound CCCCCCl SQCZQTSHSZLZIQ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FXNDIJDIPNCZQJ-UHFFFAOYSA-N 2,4,4-trimethylpent-1-ene Chemical group CC(=C)CC(C)(C)C FXNDIJDIPNCZQJ-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 206010016454 Femur fracture Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010031149 Osteitis Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 208000005250 Spontaneous Fractures Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 208000018339 bone inflammation disease Diseases 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000012869 germination medium Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 201000006409 renal osteodystrophy Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
Abstract
The present invention relates to a composition for preventing or treating obesity or bone metabolism diseases, which comprises germinated brown rice extract as an active ingredient. The germination brown rice extract of the present invention inhibits the expression of aP2, CD36 and PPARγ, genes involved in differentiation of adipocytes, (BMD) and bone strength in an ovariectomized osteoporosis animal model, and is useful for bone metabolic diseases such as obesity and osteoporosis, osteoporosis, or fracture, by promoting the expression of ALP, osterix and Runx2, It can be used as medicine or health functional food.
Description
The present invention relates to a composition for preventing or treating obesity or bone metabolism diseases, which comprises germinated black rice extract as an active ingredient. The composition of the present invention is useful as a health functional food for preventing and treating bone metabolism such as obesity or osteoporosis, And in the manufacture of pharmaceuticals.
Osteoporosis refers to a skeletal disorder in which the risk of fracture and bone fragility are increased due to low bone mass and bone destruction. Osteoporosis is a particularly frequent occurrence in postmenopausal women, a disease in which the amount of bone is markedly reduced by the decreased secretion of estrogen. The decrease in the amount of bone may be due to individual differences or various other causes, but if the amount of bone excessively decreases and falls below a predetermined value, fracture easily occurs even in a small impact. Osteoporosis can not lead to a healthy life by restricting long-term activities due to various fractures caused by weakening of the bones, especially femur fracture or vertebral fracture, rather than the symptom itself, resulting in 15% of the elderly death It is known.
Osteodystrophy is also called bone dystrophy and is a bone disease caused by chronic renal failure. It is born by abnormally abnormal kidney function, and when the kidney is weak, it does not dialyse. This kind of bone disease is called Renal Osteodystrophy. Bone diseases associated with osteophagia include osteomalacia fibrous osteitis (osteitis fibrosa).
On the other hand, black rice (Oryza sative L) is native to Thailand and has been cultivated in Jindo since 1991 in Korea. Black rice contains a large amount of selenium, and it has cancer prevention effect. There is a recent report in China that 40 patients with rectal cancer were treated with black rice for a prolonged period of time and the condition improved.
In 1998, professor Hwang Tae-Ik of the agriculture department of Chonnam National University also reported that the black rice has excellent efficacy in cancer cell removal and gastric ulcer treatment. In addition, vitamin B and vitamin E in black rice contains more than four times as much as ordinary rice, and it is effective for prevention of diabetes and adult diseases as well as female beauty.
As such, various studies have been conducted in the field of disease treatment or health functional food using black rice.
However, there is a growing interest in germinated grains as a health food, but there is little research on its efficacy in germinated black rice.
SUMMARY OF THE INVENTION The present invention has been made in view of the above problems, and an object of the present invention is to provide a composition for preventing or treating obesity or bone metabolic diseases derived from germinated brown rice, and to produce a health functional food or a pharmaceutical product therefrom.
One aspect of the present invention is to provide a composition for preventing or treating obesity or bone metabolism diseases containing germinated black rice extract as an active ingredient.
Another aspect of the present invention is to provide a health functional food for preventing or ameliorating obesity or bone metabolism diseases containing germinated black rice extract as an active ingredient.
The germinated black rice extract of the present invention inhibits the expression of aP2, CD36 and PPAR.gamma., Genes involved in differentiation of adipocytes, promotes the expression of ALP, osterix and Runx2, genes involved in osteoblast differentiation, and promotes ovariectomized osteoporosis animal model (BMD) and bone strength, and can be used as medicines or health functional foods useful for bone metabolism diseases such as obesity and osteoporosis, osteoporosis or fracture.
In addition, the germinated black rice extract of the present invention is superior in extract yield, adipocyte differentiation inhibiting activity and osteoblast differentiation promoting activity to black rice extract, and further enhances bone density and bone strength in an ovariectomized osteoporosis animal model, It is possible to provide a medicine or a health functional food having a more excellent effect on bone metabolic diseases.
1 is a graph showing an effect of inhibiting adipocyte differentiation of germinated brown rice water extracts according to germination period according to Experimental Example 2-1 of the present invention.
FIG. 2 is a graph showing relative mRNA expression levels of adipocyte-forming differentiation factors (aP2, CD36 and PPARγ) by germinated black rice water extract according to germination period according to Experimental Example 2-2 of the present invention.
FIG. 3 shows the result of ALP staining for confirming osteoblast differentiation promotion effect of germinated black rice water extract according to germination period according to Experimental Example 3-1 of the present invention.
FIG. 4 is a graph illustrating numerical results of the ALP staining shown in FIG. 3 by programming.
FIG. 5 is a graph showing relative mRNA expression levels of osteoblast-related differentiation factors (ALP, Osterix, and Runx2) by germinated black rice water extracts according to germination period according to Experimental Example 3-2 of the present invention.
6 is a graph showing an effect of inhibiting adipocyte differentiation of germinated black rice water extract according to the type of LED light source according to Experimental Example 4-1 of the present invention.
FIG. 7 is a graph showing relative mRNA expression levels of adipocyte-forming differentiation factors (aP2, CD36 and PPARγ) by germinated black rice water extract according to the LED light source type according to Experimental Example 4-2 of the present invention.
FIG. 8 shows results of ALP staining for confirming osteoblast differentiation promotion effect of germinated black rice water extract according to the LED light source type according to Experimental Example 5-1 of the present invention.
FIG. 9 is a graph obtained by digitizing the result of ALP staining shown in FIG. 8 by programming.
10 is a graph showing relative mRNA expression levels of osteoblast-related differentiation factors (ALP, Osterix, and Runx2) by germinated black rice water extract according to the LED light source type according to Experimental Example 5-2 of the present invention.
FIG. 11 is a graph showing the results of the ovariectomy (OVX), the ovariectomy (OVX), the ovariectomy (OVX + BRW) and the ovariectomy (OVX + 3 GBRW) treated with germinated brown rice water extract of
FIG. 12 is a graph showing the bone mineral density of each experimental group when the rat was 19 weeks old in Experimental Example 6. FIG. In Fig. 12, * is P < 0.05, ** is P < 0.005, *** is P <
FIG. 13 is a graph showing the bone strength of each experimental group when the rat became 19 weeks old in Experimental Example 6. FIG. In Fig. 13, * is P < 0.05, ** is P < 0.005, *** is P <
Hereinafter, the present invention will be described in more detail.
The composition for preventing or treating bone metabolic diseases according to the present invention contains germinated black rice extract as an active ingredient.
As used herein, the term " comprising as an active ingredient " means an amount sufficient to achieve the efficacy or activity of the black rice extract.
The bone metabolic diseases of the present invention include osteoporosis, bone formation disorder or fracture.
In the present invention, 'osteoporosis' includes clinical classification according to the measurement of bone mineral density (BMD), ie, osteopenia, osteoporosis, and severe osteoporosis. It also includes primary osteoporosis type 1 (postmenopausal osteoporosis type 1),
In the present invention, 'osteodystrophy' includes osteomalacia, osteitis fibrosa and the like.
In the present invention, 'fracture' refers to a state in which the continuity of bone or cartilage is completely or incompletely lost or a linear deformation occurs. Fractures are pathologic fractures caused by osteoporosis and tumor osteomyelitis, which are anatomical location, extent of fracture, direction of fracture, presence of open window, number of fractures, stability, dislocation of fracture, And fatigue fractures caused by being applied, and the term "fracture" includes all of them.
The extract of the present invention may be an extract of water containing purified water, an organic solvent having 1 to 4 carbon atoms, or a mixed solvent thereof. In addition, the organic solvent having 1 to 4 carbon atoms may contain a polar solvent such as acetic acid, dimethyl-formamide (DMFO) or dimethyl sulfoxide (DMSO), acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, , 4-trimethylpentane, decane, cyclohexane, cyclopentane, diisobutylene, 1-pentene, 1-chlorobutane, 1- chloropentane, o-xylene, diisopropyl ether, 2- chloropropane, Non-polar solvents such as 1-chloropropane, chlorobenzene, benzene, diethyl ether, diethyl sulfide, 1,2-dichloroethane, anniline, diethylamine, ether, carbon tetrachloride and THF (tetrahydrofuran) may be used.
The term 'extract' used in the present invention includes fractions obtained by further fractionating the above extract. That is, the present invention can be applied not only to water, an organic solvent having 1 to 4 carbon atoms, a nonpolar solvent or a mixed solvent thereof, but also a fraction obtained by fractionation with the above solvents or an ultrafiltration membrane having various molecular weights or a constant molecular weight cut- And fractions obtained.
The method for producing the extract of the present invention can be carried out by, for example, drying and finishing germinated brown rice, and then adding water, which is about 1 to 50 times, preferably about 10 to 40 times the weight of the dried sample, Organic solvent or a mixed solvent thereof at a temperature of 20 to 100 ° C., preferably 40 to 60 ° C. for about 24 hours or for 2 to 4 hours under stirring, hot-water extraction, cold extraction, Or an extract method such as supercritical extraction, preferably extracting hot water, and extracting the obtained extract, by filtration, concentration under reduced pressure or drying to obtain the extract of the present invention.
The germinated black rice used in the extraction of germinated black rice of the present invention may be germinated for 3 days or more. If the germination period is less than 3 days, the extraction yield and the activity of inhibiting adipocyte differentiation may be lowered. In addition, since the osteoblast differentiation increasing activity is improved as the germination period is increased, the germination period can be 3 days or more, preferably 3 days or more, in consideration of the extraction yield, the adipocyte differentiation inhibiting activity, Germinated black rice germinated for 6 days can be used.
In addition, the germinated black rice used in the extraction of germinated black rice according to the present invention may be a LED (Light Emitting Diode) light source, preferably a VLED (Visible Light Emitting Diode) light source of a visible light region and a white light source ). ≪ / RTI >
The LED light sources can be classified into light sources of various colors as shown in Table 1 according to wavelengths. By mixing two or more colors selected from red, green and blue, which are the basic light source colors of LEDs, Can be implemented.
The germinated black rice extract obtained by using germinated black rice obtained from the dark room shows excellent extraction yield, adipocyte differentiation inhibiting activity and osteoblast differentiation increasing activity. However, in case of germinated black rice extract obtained from germinated black rice germinated under LED light source, It is possible to demonstrate the same level of inhibition of adipocyte differentiation compared to germinated black rice extract obtained from germinated black rice germinated in the dark room, and further improved extraction yield and osteoblast differentiation increasing activity.
The germinated black rice extract obtained by using the germinated black rice germinated under the LED light source may have an increased extraction yield compared to the germinated black germ extract obtained using the germinated black rice germinated in the dark room. Here, the LED light source may include an orange of 590 <? 620 nm, a yellow light source of 570 <? 590 nm, a green light source of 490 <? 570 nm, a light source of 450 < A blue light source of? 490 nm wavelength, a violet light source of 420?? 450 nm wavelength, and a purple light source of 380?? 420 nm wavelength band.
In particular, the germinated black rice extract obtained from germinated black rice germinated under the light sources of Blue, Purple and Mix among the LED light sources exhibits an equivalent level of inhibition of adipocyte differentiation compared to the germinated black rice extract germinated in the dark room.
Among the LED light sources, the germinated black rice extract obtained from germinated black rice germinated under the orange, green and blue light sources exhibits enhanced osteoblast differentiation activity compared to the germinated black rice extract germinated in the dark room.
Accordingly, among the LED light sources, the germinated black rice extract obtained from germinated black rice germinated under a blue light source having a wavelength of 450?? 490 nm can exhibit excellent extraction yield, adipocyte differentiation inhibiting activity and osteoblast differentiation increasing activity.
The composition for preventing or treating obesity or bone metabolism diseases comprising germinated black rice extract of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the production of pharmaceutical compositions.
The composition containing the extract according to the present invention may be formulated in the form of powders, granules, tablets, capsules, oral preparations such as suspensions, emulsions, syrups and aerosols, external preparations, suppositories and sterilized injection solutions, Can be used.
Examples of carriers, excipients and diluents that can be included in the composition containing the germinated black rice extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate , Calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose ), Lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
The preferred dosage of the germinated black rice extract of the present invention varies depending on the condition and body weight of the patient, the degree of disease, the type of drug, the administration route and the period of time, but can be appropriately selected by the therapist. However, for the desired effect, the extract of the present invention is preferably administered at a dose of 0.01 mg / kg to 10 g / kg per day, preferably 1 mg / kg to 1 g / kg per day. The administration may be carried out once a day or divided into several doses. Accordingly, the dosage is not limited in any way to the scope of the present invention.
The composition of the present invention may be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections.
The present invention provides a health functional food for preventing or ameliorating obesity or bone metabolic diseases, which comprises an extract of germinated brown rice showing an activity of inhibiting adipocyte differentiation, an osteoblast differentiation increasing activity and a bone mineral density increasing activity, and a pharmaceutically acceptable food supplementary additive.
The health functional food of the present invention includes various foods, gums, tea, vitamin complex, health supplement foods and the like, and can be used as powder, granule, tablet, capsule or beverage.
Since the germination black rice extract of the present invention has little toxicity and side effects, it can be safely used for prolonged use even for prophylactic purposes.
When the germinated black rice extract of the present invention is added to a food or beverage for the purpose of preventing or improving obesity or bone metabolic diseases, the amount of the extract in the food or beverage is generally from 0.01 to 15 wt% %, And the health beverage composition can be added at a ratio of 0.02 to 10 g, preferably 0.3 to 1 g, based on 100 ml.
The health beverage composition of the present invention may contain various flavors or natural carbohydrates such as ordinary beverages as an additional ingredient, as long as it contains the extract as an essential ingredient at the indicated ratio, and there is no particular limitation to the liquid ingredient. Examples of the above-mentioned natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrin, cyclodextrin and the like Sugar, and sugar alcohols such as xylitol, sorbitol, and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
In addition to the above, the health functional food of the present invention may contain flavorings such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and heavies (cheese, chocolate etc.), pectic acid and its salts, And salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the health functional foods of the present invention may contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not so important, but is generally selected in the range of 0.1 to about 20 parts by weight per 100 parts by weight of the health functional food of the present invention.
Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples. However, the following examples and experimental examples are illustrative of the present invention, and the present invention is not limited thereto.
Significant differences between the experimental groups were tested at the p <0.05 level using Analysis of Variance (ANOVA) and Duncan's multiple range test. The same characters in the results of the experimental group showed no statistical significance and there was a significant difference between the different characters.
Production Example 1: Preparation of black rice and germinated brown rice water extract (darkroom germination)
The black rice used in the present invention was harvested directly from the National Institute of Food Science and Technology, Milyang Rural Development Administration, Gyeongsangnam-do. The harvested black rice was soaked in a 30-fold diluted sodium hypochlorite solution at 30 ° C for 24 hours and washed with water. Then, it was spread evenly on the base plate, filled with water at a height of about 1/2 to 2/3 of the Japanese black rice, germinated and germinated in the dark room at a temperature of 30 ° C.
Germinated black rice was obtained in 1 day or 2 days during the germination period, and germinated black rice water extract was prepared for each germinated black rice in the following manner. The germination period was a total of 6 days and germinated black rice was obtained at 0 day, 1st day, 2nd day, 3rd day, 4th day and 6th day respectively, and 0th day means black rice before germination.
The black rice and the sprouted black rice were completely dried, and finely pulverized to obtain a powdery sample.
Water was added to the
Production Example 2: Production of black rice and germinated brown rice ethanol extract (darkroom germination)
The same powder sample as in Production Example 1 was prepared.
400 ml of a 70% by weight aqueous ethanol solution was added to 20 g of the powder sample, and the mixture was firstly extracted at 120 rpm and 60 ° C. for 24 hours in a shaking incubator. The supernatant was filtered with a Whatman No.1 filter paper, 400 ml of a 70% by weight aqueous ethanol solution was added per 20 g of the sample, and the mixture was extracted again for 24 hours and filtered in the same manner as described above. The filtrate was concentrated under reduced pressure at 45 ° C with a rotary vacuum evaporator and the solvent was completely blown off to obtain a 70 wt% ethanol extract of black rice and a 70 wt% ethanol extract of germinated black rice.
Comparative Preparation Example 1 Preparation of black rice and germinated black rice acetone extract (darkroom germination)
Using acetone as an extraction solvent, black rice and germinated black rice acetone extracts were prepared in the same manner as in Production Example 2.
Experimental Example 1: Germination period and extraction yield of germinated black rice according to extraction solvent
The extraction yields of the water extract and 70% ethanol extract of germinated black rice germinated in the dark and dark rooms prepared in Preparation Examples 1 and 2 were measured and are shown in Table 2.
As shown in Table 2, the extraction yield of germinated black rice was higher than that of the black extract before germination (0 day difference), the water extract and the 70 wt% Ethanol extracts showed higher germination yield.
The water extract and the 70 wt% ethanol extract were found to have an excellent extraction yield, and the water extract and the 70 wt% ethanol extract had the same yields. However, the extraction yield of the water extract was somewhat higher appear.
Therefore, the water extract of Preparation Example 1 having a high extraction yield from the extracts was used to test the effect of germination time on the differentiation of adipocytes and the effect of osteoclast differentiation.
Experimental Example 2: Inhibition effect of germination water on the differentiation of adipocyte according to the duration of black rice and germination
2-1. Inhibition of adipocyte differentiation in C3H10T1 / 2 cells
The C3H10T1 / 2 cell line derived from mouse embryonic fibroblasts is a pluripotent stem cell line that can differentiate into various cell lines including osteoblasts and adipocytes.
The C3H10T1 / 2 cell line was cultured in adipocyte differentiation medium containing 1 uM dexamethasone, 5 ug / ml insulin and 20 nM PPARγ for adipocyte differentiation at a concentration of 2.5 × 10 4 / ml.
The adipocyte differentiation medium was cultured for 10 days at a rate of 20 ug / ml for each germination period of germination period according to the germination period of the preparation example 1, and then the inhibition effect on the adipocyte differentiation by the germination period was measured. Respectively. At this time, the addition of DMSO alone without addition of the germinated black rice water extract according to germination period of Preparation Example 1 was used as a negative control (Control).
In FIG. 1, it was found that the water extract of germinated black rice having a germination period of 3 days or more improved the effect of inhibiting adipocyte differentiation compared to the water extract of black rice (day 0) before germination.
2-2. Analysis of adipocyte differentiation factor expression through real-time RT-PCR
The C3H10T1 / 2 cell line was treated with the germination medium for germination period of 9 days for the germination period of the adipocyte differentiation medium and the germination period of the preparation example 1, and then aP2, CD36 and PPARγ The relative mRNA expression level of the mRNA was determined and shown in Fig.
2, the expression level of adipocyte differentiation factor was decreased compared to the water extract of germinated black rice before germination (0th day) in germinated black rice with germination period of 3 days or more, and the same tendency as the inhibition of adipocyte differentiation shown in Fig. 1 .
Experimental Example 3: Promoting osteoblast differentiation promoting effect of germinated brown rice water extracts on black rice and germination period
3-1. ALP (alkaline phosphatase) staining
The C3H10T1 / 2 cell line derived from mouse embryonic fibroblasts is a pluripotent stem cell line that can differentiate into various cell lines including osteoblasts and adipocytes.
The C3H10T1 / 2 cell line was cultured in DMEM medium supplemented with 10% FBS, 1% penicillin and streptomycin at 37 ° C in a 5
The germination period of the germination period of Preparation Example 1 and the addition of distilled water (DW) alone were used as a negative control. The germination period of germination period according to germination period of ALP Dyeing results for activity confirmation and numerical values obtained by programming the result of the dyeing are shown in FIG. 3 and FIG. 4, respectively.
In the case of lipid differentiation, the stained cells could be dissolved, and the absorbance was measured to obtain the result. In the case of ALP staining, the plate was scanned through a scanner, and the result was calculated as Lab value to obtain FIG. 4 (Lab: L * a * b * In L * a * b * color space, L * indicates brightness, L * = 0 means black, L * = 100 means white, a * indicates either red or green B * is yellow and blue, b * is negative if b * is positive, and yellow if b * is positive.) If a * is negative, it is a green color. ALP staining is indicated by the -b value in the Lab color value because it is blue when the bone differentiation activity is higher.
3 and 4, it was confirmed that ALP activity of the germinated black rice extract was increased as the germination period was increased.
3-2. Analysis of osteoblast differentiation factor expression through real-time RT-PCR
5 shows the mRNA expression levels of ALP, Osterix and Runx2, which are the differentiation factors involved in osteoblast formation, by real-time PCR after differentiating C3H10T1 / 2 cells for 3 days from the above 3-1 .
FIG. 5 shows that the mRNA expression levels of ALP, osterix and Runx2 in the group treated with germinated black rice water extract were significantly increased compared to the group treated with black water extract. As the germination period was increased, the amount of mRNA expression of ALP, osterix and Runx2 was increased in the groups treated with the germinated black rice water extract, and there was no significant difference in germination date, indicating the same tendency as in FIGS. 3 and 4 .
In the Experimental Example 2 and Experimental Example 3, the effect of the germinated brown rice water extract on
Production Example 3: Preparation of germinated black rice water extracts according to LED light sources
Germinated brown rice water extract was prepared by the same method as in Production Example 1 except that the germinated brown rice water extract was prepared under an LED light source instead of the dark room and the extraction yields thereof are shown in Table 3. [ At this time, the extraction yield of germinated black rice water extract according to the type of LED light source was measured by different kinds of LED light sources, and the dark germination group of Preparation Example 1 was used as a control group.
Production Example 1 (Germination Day 3)
As shown in Table 2, the extraction yield of germinated black rice water extract was improved when germinated under an LED light source, compared to when germinated black rice was germinated in a dark room.
Among the LED light sources, the extraction yield of germinated black rice water extracts obtained under the orange, blue, purple and mix (white) light sources was high.
Experimental Example 4: Inhibitory effect of germinated black rice water extract on adipocyte differentiation depending on the type of LED light source
4-1. Inhibition of adipocyte differentiation in C3H10T1 / 2 cells
The C3H10T1 / 2 cell line derived from mouse embryonic fibroblasts is a pluripotent stem cell line that can differentiate into various cell lines including osteoblasts and adipocytes.
The C3H10T1 / 2 cell line was cultured in adipocyte differentiation medium containing 1 uM dexamethasone, 5 ug / ml insulin and 20 nM PPARγ for adipocyte differentiation at a concentration of 2.5 × 10 4 / ml.
The germinated brown rice water extracts of the germinated third day of germination according to the LED light source of Preparation Example 3 were added to the adipocyte differentiation medium in an amount of 20 ug / ml each for 9 days and then the germinated brown rice water extract The adipocyte differentiation inhibitory effect was measured and the results are shown in Fig. At this time, the addition of distilled water (DW) alone to the germinated black rice water extract of
In FIG. 6, germinated black rice water extracts obtained from Blue, Purple and Mix light sources of LED light sources showed the same level of fat cell degradation as germinated black rice water extracts obtained from Dark, It can be seen that the fat cell degradation effect of germinated brown rice water extract is not increased.
4-2. realtime RT - PCR (Fig. adipocyte Analysis of differentiation factor expression
The C3H10T1 / 2 cell line was treated with the adipocyte differentiation medium and germinated brown rice water extract of
In FIG. 7, the germinated brown rice water extract obtained under the blue, purple and mixed light sources of the LED light source showed the same level of fat cell degradation as the germinated brown rice water extract obtained from the dark room. The same tendency as that of cell differentiation inhibition was shown.
From this, it can be seen that the degradation effect of the germinated black rice water extract is not increased by the LED light source.
EXPERIMENTAL EXAMPLE 5: Promoting osteoblast differentiation promoting effect of germinated black rice water extract according to kinds of LED light sources
5-1. ALP (alkaline phosphatase) staining
The C3H10T1 / 2 cell line derived from mouse embryonic fibroblasts is a pluripotent stem cell line that can differentiate into various cell lines including osteoblasts and adipocytes.
The C3H10T1 / 2 cell line was cultured in DMEM medium supplemented with 10% FBS, 1% penicillin and streptomycin at 37 ° C in a 5
The addition of distilled water (DW) without addition of the germinated black rice water extract of the germinated third day of germination according to the LED light source of Preparation Example 3 was used as a negative control, and germination according to the LED light source of Preparation Example 3 Dyeing results for confirming ALP activity according to the kinds of LEDs of germinated black rice water extract on
8 and 9, it was confirmed that the germinated brown rice water extract of
5-2. Analysis of osteoblast differentiation factor expression through real-time RT-PCR
In the above 5-1, C3H10T1 / 2 cells were differentiated for 6 days using the germination brown rice extract of
In FIG. 10, the mRNA expression levels of ALP, Osterix and Runx2 in the group treated with germinated black rice extract of
Experimental Example 6: Ovariectomy of germinated black rice water extract (ovariectomy) Test using an animal model of osteoporosis
To examine the effect of the water extract of black rice (BRW) of Preparation Example 1 and germinated black rice water extract (3 GBRW) of
6-1. Animal breeding and ovariectomy
Ten-week-old female SD rats were purchased from Orient Biotech and had a purifying period of one week. At 11 weeks of age, ovariectomies were performed and there was a one week recovery period. Experimental animals were housed in a single cage. The environmental conditions were adjusted to room temperature 24 ± 2 ℃, relative humidity 55 ± 10%, and
Experimental animals were divided into three groups. Ten experimental ovariectomized group (SHAM), 10 ovariectomized group (OVX) and 10 ovariectomized group were treated with lateral resection. (OVX + 3 GBRW 100 mg / kg) administered with the germinated brown rice water extract (3 GBRW) of the
As a result, the ovariectomy group (OVX) showed a tendency to increase in body weight compared to the ovariectomized group (SHAM) due to the decrease of oestrogen secretion due to ovariectomy, and the brown rice water extract (OVX + BRW 100 mg / kg) and the control group (OVX + 3 GBRW) administered with the germinated brown rice water extract of the
6-2. BMD measurement
When the animal was 19 weeks of age, the femur and tibia were separated and the femur was used to measure bone density. BMD was measured using pDEXA ® (Forearm: X-Ray, NORLAND, Bone Densitometer, USA).
As a result, the BMD of the ovariectomized group (OVX) was significantly lower than that of the ovariectomized group (SHAM), and the ovariectomized BMD of the experimental group (OVX) (OVX + 3 GBRW) of the germinated brown rice water extract of
6-3. Bone Strength (BS) Measurement
(OVx + BRW) in which the black water extract of Preparation Example 1 was administered (Ovx + BRW) after the ovariectomy, and the
As a result, the bone strength (BS) of the ovariectomized group (OVX) was not significantly different from that of the ovariectomized group (SHAM) but it was decreased to some extent. After ovariectomy, the brown rice water extract of Preparation Example 1 was administered The bone strength (BS) of one experimental group (Ovx + BRW) was higher than that of ovariectomized group (OVX), but there was no significant difference. Also, in the experimental group (OVX + 3 GBRW) showed a significant increase in bone strength as compared to the experimental group (OVX + BRW) to which the black rice water extract of Preparation Example 1 was administered (FIG. 13).
Hereinafter, formulation examples of the composition containing the extract of the present invention will be described, but the present invention is not intended to be limited thereto but is specifically described. The germinated brown rice water extract used in Formulation Examples 1 to 7 was the germinated brown rice water extract of
Preparation Example 1. Preparation of powder
20 mg of the germinated brown rice water extract of Preparation Example 3-5
Lactose 100 mg
The above components are mixed and filled in airtight bags to prepare powders.
Formulation Example 2. Preparation of tablets
10 mg of the germinated brown rice water extract of Preparation Example 3-5
Corn starch 100 mg
Lactose 100 mg
After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.
Formulation Example 3. Preparation of capsules
10 mg of the germinated brown rice water extract of Preparation Example 3-5
Lactose 14.8 mg
Magnesium stearate 0.2 mg
The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.
Formulation Example 4. Preparation of injection
10 mg of the germinated brown rice water extract of Preparation Example 3-5
180 mg mannitol
Sterile sterilized water for injection 2974 mg
Na 2 HPO 4, 12H 2 O 26 mg
(2 ml) per 1 ampoule according to the usual injection preparation method.
Formulation Example 5. Preparation of a liquid preparation
20 mg of the germinated brown rice water extract of Preparation Example 3-5
10 g per isomer
5 g mannitol
Purified water quantity
Each component was added to purified water in accordance with the usual liquid preparation method and dissolved, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was adjusted to 100 ml with purified water, And sterilized to prepare a liquid preparation.
Formulation Example 6. Preparation of Healthy Foods
1,000 mg of the germinated brown rice water extract of Preparation Example 3-5
Vitamin mixture quantity
70 [mu] g of vitamin A acetate
Vitamin E 1.0 mg
0.13 mg vitamin B1
0.15 mg of vitamin B2
0.5 mg vitamin B6
0.2 [mu] g vitamin B12
10 mg vitamin C
Biotin 10 μg
Nicotinic acid amide 1.7 mg
50 ㎍ of folic acid
Calcium pantothenate 0.5 mg
Mineral mixture quantity
1.75 mg of ferrous sulfate
0.82 mg of zinc oxide
Magnesium carbonate 25.3 mg
15 mg of potassium phosphate monobasic
Secondary calcium phosphate 55 mg
Potassium citrate 90 mg
100 mg of calcium carbonate
24.8 mg of magnesium chloride
Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
Formulation Example 7. Preparation of health drink
1,000 mg of the germinated brown rice water extract of Preparation Example 3-5
Citric acid 1,000 mg
100 g of oligosaccharide
Plum concentrate 2 g
Taurine 1 g
The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring, and the resulting solution was filtered to obtain a sterilized 2-liter container, which was sealed and then refrigerated And then used in the production of the health beverage composition of the present invention.
Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.
It will be apparent to those skilled in the art that the present invention is not limited to the embodiments described above and that various changes and modifications may be made without departing from the spirit and scope of the present invention as defined by the appended claims. As shown in FIG.
It will be understood by those skilled in the art that the present invention may be embodied in many other specific forms without departing from the spirit or scope of the invention as defined by the appended claims and their equivalents. .
Claims (13)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150176560A KR20170069413A (en) | 2015-12-11 | 2015-12-11 | Composition comprising extract of germinated black rice as an effective component for prevention or treatment of obesity or of metabolic bone disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150176560A KR20170069413A (en) | 2015-12-11 | 2015-12-11 | Composition comprising extract of germinated black rice as an effective component for prevention or treatment of obesity or of metabolic bone disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20170069413A true KR20170069413A (en) | 2017-06-21 |
Family
ID=59281587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150176560A KR20170069413A (en) | 2015-12-11 | 2015-12-11 | Composition comprising extract of germinated black rice as an effective component for prevention or treatment of obesity or of metabolic bone disease |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20170069413A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3542811A1 (en) * | 2018-03-20 | 2019-09-25 | Wellbeinggo Co., Ltd. | Black rice sprouting liquid having anti-inflammatory effect and manufacturing method thereof |
| KR20190109308A (en) * | 2018-03-15 | 2019-09-25 | 건국대학교 글로컬산학협력단 | Composition for preventing and treating of bone diseases comprising fermented extracts from aronia and black rice |
-
2015
- 2015-12-11 KR KR1020150176560A patent/KR20170069413A/en not_active Application Discontinuation
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190109308A (en) * | 2018-03-15 | 2019-09-25 | 건국대학교 글로컬산학협력단 | Composition for preventing and treating of bone diseases comprising fermented extracts from aronia and black rice |
| EP3542811A1 (en) * | 2018-03-20 | 2019-09-25 | Wellbeinggo Co., Ltd. | Black rice sprouting liquid having anti-inflammatory effect and manufacturing method thereof |
| WO2019182313A1 (en) * | 2018-03-20 | 2019-09-26 | 웰빙고 주식회사 | Black rice germination liquid having anti-inflammatory effect and method for preparing same |
| CN111989000A (en) * | 2018-03-20 | 2020-11-24 | 万贝谷株式会社 | Black rice sprouting liquid with anti-inflammatory effect and preparation method thereof |
| JP2021518442A (en) * | 2018-03-20 | 2021-08-02 | ウェル ビーイング ゴー カンパニー リミテッドWell Being Go Co., Ltd | Black rice germination solution with anti-inflammatory effect and its manufacturing method |
| CN111989000B (en) * | 2018-03-20 | 2023-11-28 | 万贝谷株式会社 | Black rice sprouting liquid with anti-inflammatory effect and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101686490B1 (en) | Composition comprising extract of black rice as an effective component for prevention or treatment of metabolic bone disease | |
| KR100813222B1 (en) | Medicinal herbal extract having anti-obesity effect | |
| JP2010132703A (en) | Galenical extract mixture and agent for preventing or curing osteoporosis | |
| KR20210020988A (en) | Composition for stimulation of bone formation comprising xanthorrhizol as effective component | |
| KR20170069413A (en) | Composition comprising extract of germinated black rice as an effective component for prevention or treatment of obesity or of metabolic bone disease | |
| KR102081984B1 (en) | A pharmaceutical composition comprising extract from wheat sprowt for preventing or treating osteoporosis | |
| KR101888871B1 (en) | Composition for preventing and treating of obesity or metabolic disease comprising extract from leaf of Plantago asiatica | |
| KR102070312B1 (en) | COMPOSITION FOR BONE GROWTH PROMOTING COMPRISING Allium fistulosum L. AS AN ACTIVE INGREDIENT | |
| KR101075554B1 (en) | Composition for the prevention and treatment of postmenopausal syndrome containing extracts or fractions of Aceriphyllum rossii as an effective ingredient | |
| KR101052501B1 (en) | Composition for the prevention and treatment of bone diseases containing herbal extract as an active ingredient | |
| KR20200014566A (en) | A composition for improving, preventing and treating of arthritis comprising Milk thistle and Achyranthes bidentata Blume | |
| KR101885667B1 (en) | Extract of Oryza sativa for promoting osteoblast differentiation and its use | |
| KR101249930B1 (en) | Compositions comprising extracts of Sorbus commixta and Geranium nepalense for inhibiting osteoclastogenesis and stimulating chondrogenesis | |
| KR101972657B1 (en) | Composition comprising extract of Angelica decursiva Franchet et Savatieras or compounds isolated therefrom for preventing or treating osteoporosis | |
| KR20210012915A (en) | A pharmaceutical composition for preventing or treating inflammatory bone joint diseases comprising an enzyme-treated royal jelly powder | |
| WO2008007880A1 (en) | A composition comprising an extract of prunus persica (l.) batsch for treating and preventing bone diseases | |
| KR100640094B1 (en) | Composition comprising the seed oil of Green Tea having Cholesterol-lowering or antioxidant activity | |
| KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
| KR20100098317A (en) | Composition for preventing and treating bone diseases | |
| KR101364690B1 (en) | Composition for promoting bone growth comprising bamboo | |
| KR101569078B1 (en) | Composition comprising extract of Phragmites spp. as an effective component for prevention or treatment of metabolic bone disease | |
| KR102312736B1 (en) | A composition for bone health comprising winter melon extract | |
| KR20130091160A (en) | A composition for treating the osteoporosis comprising artemisia capillaris t. extract | |
| KR102312737B1 (en) | A composition for bone health comprising winter melon seed extract | |
| KR20170140651A (en) | A composition for the treatment or prevention of osteoporosis comprising an extract of honey berry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application | ||
| J201 | Request for trial against refusal decision | ||
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2017101002604; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20170529 Effective date: 20180122 |